A61K39/464444

Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-? receptor II (dnTGF?RII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).

METHODS FOR SELECTIVELY MODULATING THE ACTIVITY OF DISTINCT SUBTYPES OF CELLS

The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.

Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells
20240277768 · 2024-08-22 ·

Compositions comprising one or more peptide fragments of preproinsulin for treating type 1 diabetes mellitus (T1DM) autoimmunity, methods of treating T1DM autoimmunity using such compositions, and kits comprising such compositions for diagnosing and/or treating TIDM autoimmunity.